77 results
Page 3 of 4
6-K
EX-99.1
n78c0uzosslyvimhdwcc
15 Jan 21
ERYTECH Announces First Patient Enrolled in Eryaspase in First-Line Pancreatic Cancer
12:35pm
6-K
EX-99.1
jk78jv1s
15 Dec 20
ERYTECH Completes Enrollment in TRYbeCA-1
8:16am
6-K
EX-99
b2i11
7 Dec 20
Current report (foreign)
10:14am
6-K
EX-99.1
bva35a5chzm3 hytq0
6 Nov 20
ERYTECH Announces Abstract with Results from Eryaspase
9:24am
6-K
EX-99.2
b9yh186jn5p77bde5f00
6 Nov 20
ERYTECH Announces Abstract with Results from Eryaspase
9:24am
6-K
EX-99.1
x0q ev2ca4bc3
3 Nov 20
ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government
4:33pm
424B5
rtiiimqo
9 Oct 20
Prospectus supplement for primary offering
5:16pm
6-K
EX-99.1
zdn6erg
22 Sep 20
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020
12:00am
6-K
EX-99.2
arubt agm
22 Sep 20
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020
12:00am
F-3
8o46pd6
21 Sep 20
Shelf registration (foreign)
5:26pm
6-K
EX-99.1
n6bxh
15 Sep 20
ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment
7:32am
6-K
EX-99.1
t4o47nn5ne40wrpgp0
26 Jun 20
Current report (foreign)
5:10pm
6-K
EX-99.1
zzv101vrjg3x gq
9 Jun 20
ERYTECH Provides Update on Phase 2 Investigator
4:11pm
6-K
EX-99.1
9fd5exgdfs
2 Jun 20
ERYTECH Announces Poster Presentations
5:07pm
6-K
EX-99.1
m0jdco6wte58js3b
26 May 20
Erytech’s Combined Shareholders’ Meeting
4:40pm
6-K
EX-99.1
wbknsvbfmq29b7rxwq
8 May 20
ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020
4:08pm
6-K
EX-99.1
l11rl 2fkvbi80
30 Apr 20
ERYTECH Granted U.S. FDA Fast Track Designation
7:59am
6-K
EX-99.1
k6kfi tuc5l
21 Apr 20
ERYTECH Provides Update on theTRYbeCA-1
7:06am
6-K
EX-99.1
frjduvo3g067
17 Mar 20
ERYTECH Announces the Appointment of
4:25pm